REVAGENIX INC - TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES.

On Dec 23, 2025, Department of Health and Human Services obligated $26,944,786.61 to REVAGENIX INC for to select a novel small molecule antibiotic for clinical development and advance it through ind filing and phase 1 clinical studies.. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition with 12 offers received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in SAN DIEGO, CA. The contract is scheduled through Aug 31, 2026 — approximately 4 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.